Promore Pharma
25.10.2021 09:21:54 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 25, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Stockholm 25 October 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announces that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers has been published in the journal Wound Repair and Regeneration.
In 2020, Promore Pharma completed a clinical trial, HEAL LL-37, a phase IIb double-blind, randomized, placebo-controlled study aimed at evaluating the efficacy and safety of a new drug, LL-37 / ropocamptide for local administration in combination with compression therapy. The study was performed on 148 patients suffering from difficult-to-heal venous leg ulcers.
Today, the company announces that a scientific article has been published in the journal Wound Repair and Regeneration, which is the journal of the international society in wound care, Wound Healing Society. Co-authors of the article are several internationally renowned subject area experts, including professors Jan Apelqvist, Arkadiusz Jawien, and Folke Sjöberg.
" We are very content that the results of HEAL LL-37 are now published and available to the scientific community and the general public. The publication is a confirmation of the quality of the completed clinical study ", says Jonas Ekblom, CEO of Promore Pharma.
" Once again, we thank all the staff at the healthcare facilities who have participated in the study for their valuable contributions, " says Margit Mahlapuu, CSO of Promore Pharma.
The published article is entitled "Evaluation of LL-37 in Healing of Hard-to-Heal Venous Leg Ulcers: a Multicentric Prospective Randomized Placebo-Controlled Clinical Trial" and can be read in its entirety via the following link:
https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12977
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/669452/Promore-Pharma-Announces-that-Scientific-Article-has-Been-Published-on-Clinical-Study-Results-with-Ropocamptide-for-Venous-Leg-Ulcers
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Announces Execution of Mixed Investment Agreement for the Three Mexico Projects7.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that, further to its press release dated June 8, 2026, it has reached another important milestone in the development of its three renewable energy projects selected under Mexico's Comisión Federal de Electricidad ("CFE") Mixed Development Program (the "Mixed Program"). On July 3, 2026, Polaris, through its Mexican project structure, executed the Mixed Investment Agreement (Contrato de Inversión Mixta or "CIM") with the fiduciary trustee, Banca Mifel, S.A., Institucion de Banca Multiple, Grupo Financiero Mifel, acting on behalf of CFE. The CIM establishes the contractual 30-year framework governing the joint participation of Polaris and CFE in the development, financing, construction, ownership and operation of the three selected projects, including the applicable governance, economic and corporate arrangements. The CIM includes the key information a
Oxford University Press Comes to Simply Piano7.7.2026 10:00:00 CEST | Press release
Content from OUP's acclaimed piano method is now available to millions of Simply Piano learners worldwide NEW YORK, NY / ACCESS Newswire / July 7, 2026 / Simply, the leading digital platform for creative hobbies, today announced an agreement to bring content from Oxford University Press' (OUP) piano method to Simply Piano. This expands Simply Piano's offering and marks a step forward in its mission to make the pursuit of creative hobbies simple and fun for all. Simply Piano users around the world will gain access to an expanded library of high-quality, curated sheet music spanning OUP's works including Piano Time and Tunes for Ten Fingers, all within the app's interactive learning environment. The integration expands Simply Piano's sheet music library across genres, complementing its step-by-step courses and real-time feedback tools. "Access to songs people love is one of the strongest drivers of learning," said Yuval Kaminka, CEO & co-founder of Simply. "Working with OUP allows us to
AM Technical Solutions Acquires Sequence, Inc., Expanding Life Sciences Engineering and Commissioning, Qualification, and Validation (CQV) Capabilities7.7.2026 07:00:00 CEST | Press release
KILDARE, IRELAND / ACCESS Newswire / July 7, 2026 / AM Technical Solutions (AM), a global architecture, engineering, construction, and commissioning firm specializing in high-technology markets, announces the acquisition of Sequence, Inc., a leading engineering firm specializing in Process Design, Commissioning, Qualification, and Validation (CQV) solutions for life sciences and related high-tech industries. Sequence, headquartered in Morrisville, North Carolina, brings deep expertise in CQV, Computer System Validation (CSV), IT/OT integration, operational readiness, and life sciences engineering excellence. Their cross-functional approach to process engineering and facility startup has earned them a strong track record accelerating time to market for pharmaceutical and biopharmaceutical clients across the full project lifecycle -- from conceptual design through licensure and commercial operations. This acquisition deepens AM's existing Engineering and CQV capabilities with proven team
Crossmint Secures Payment Institution and MiCA Authorization, Completing a Full-Stack EU Regulatory Stack for Stablecoin Payments3.7.2026 21:00:00 CEST | Press release
With Authorization as a Crypto-Asset Service Provider Under MiCA and Payment Institution Under PSD2, Crossmint Now Operates Under Both of the EU's Core Frameworks for Stablecoin Infrastructure, Giving Enterprise Fintechs One Regulated Provider to Hold Stablecoins and Move Them as Payments MADRID, ES / ACCESS Newswire / July 3, 2026 / Crossmint has been authorized as a Payment Institution (PI) by the Bank of Spain under the EU's Payment Services Directive (PSD2). Earlier this year, Crossmint received MiCA class 2 authorization from Spain's CNMV, establishing complete authorization to operate as a crypto-asset service provider across the EU. After completing the required conditions, Crossmint has now successfully been fully registered as a CASP with CNMV, which allows passporting across all 27 EU member states. PSD2 authorization is the natural expansion of that compliance footprint, enabling stablecoins to be used as a means of payment under EU payments law. "Crossmint's mission is to b
Polaris Renewable Energy Announces Q2 2026 Investor Call Details3.7.2026 19:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 3, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2026 Earnings Results on Thursday, July 30th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 503447 or URL: https://www.webcaster5.com/Webcast/Page/2773/53517 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 53517 International (toll-free): 1 919-882-2331, Passcode: 53517 Encore Replay Expiration Date: August 13, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom